CVRx Q1 revenue $12.3M (+15% YoY); net loss narrows; guides FY2025 rev $55-58M

CVRx, Inc.

2025-Q1 EPS reported -$0.53 revenue$12,348,000

Total revenue $12.3M (+15% YoY); U.S. HF revenue $11.1M (+14%) on 353 implants.
Net loss $13.8M ($0.53/share) vs $22.2M ($1.04) in Q1 2024; cash $102.7M.
FY2025 revenue guidance $55-58M; Q2 revenue expected $13-14M.
Active U.S. implanting centers 227 (+19% YoY); gross margin 84%.
Real-world evidence: 85% reduction in HF hospital visits (Premier Healthcare Database).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.